Lack of association between the PIN1 promoter ‑667T>C (rs2233679) polymorphism and cancer risk: 
Evidence from meta‑analysis

Tao,Liangjun; Chen,Yisheng; Tao,Lingsong; Kong,Jian; Qin,Haibo; Zheng,Jie; Zou,Bin; He,Sizhong

doi:10.3892/br.2014.229

Lack of association between the PIN1 promoter ‑667T>C (rs2233679) polymorphism and cancer risk: Evidence from meta‑analysis

Authors:
- Liangjun Tao
- Yisheng Chen
- Lingsong Tao
- Jian Kong
- Haibo Qin
- Jie Zheng
- Bin Zou
- Sizhong He
View Affiliations

Affiliations: Department of Urology and Institute of Prostatic Diseases, The Affiliated Wuhu No. 2 People's Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China, Department of Psychiatry, The Affiliated Wuhu No. 2 People's Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China
Published online on: January 22, 2014 https://doi.org/10.3892/br.2014.229
Pages: 223-228

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peptidyl‑prolylcis‑trans isomerase NIMA-interacting 1 (PIN1) is a critical catalyst involved in multiple oncogenic signaling pathways. The PIN1 promoter ‑667T>C (rs2233679) polymorphism plays a role in cancer risk. The association between PIN1 (‑667T>C) polymorphism and cancer risk has been previously investigated. However, the available results are inconclusive. To derive a more precise estimation, a meta‑analysis of seven published case‑control studies including 4,524 cases with different tumor types and 4,561 controls was performed. Published literature from PubMed and EMBASE was retrieved. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the strength of the association. Overall, the results did not suggest any associations between the PIN1 promoter (‑667T>C) polymorphism and cancer susceptibility (OR=1.04, 95% CI: 0.91‑1.18 for CC vs. TT; OR=0.98, 95% CI: 0.89‑1.09 for TC vs. TT; OR=1.00, 95% CI: 0.91‑1.10 for TC/CC vs. TT; OR=1.07, 95% CI: 0.97‑1.18 for CC vs. TC/TT). Further stratiﬁed analysis by cancer type, ethnicity and sample size did not reveal any signiﬁcant associations in the genetic models. The results of the present study demonstrate that the PIN1 promoter (‑667T>C; rs2233679) polymorphism is not associated with cancer susceptibility.

View Figures

View References

1	Lu KP: Pinning down cell signaling, cancer and Alzheimer’s disease. Trends Biochem Sci. 29:200–209. 2004.
2	Lu KP: Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics. Cancer Cell. 4:175–180. 2003. View Article : Google Scholar : PubMed/NCBI
3	Ranganathan R, Lu KP, Hunter T and Noel JP: Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell. 89:875–886. 1997. View Article : Google Scholar : PubMed/NCBI
4	Lu KP, Hanes SD and Hunter T: A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature. 380:544–547. 1996. View Article : Google Scholar : PubMed/NCBI
5	Lu KP and Zhou XZ: The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol. 8:904–916. 2007. View Article : Google Scholar : PubMed/NCBI
6	Miyashita H, Mori S, Motegi K, Fukumoto M and Uchida T: Pin1 is overexpressed in oral squamous cell carcinoma and its levels correlate with cyclin D1 overexpression. Oncol Rep. 10:455–461. 2003.PubMed/NCBI
7	Wulf GM, Ryo A, Wulf GG, et al: Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 20:3459–3472. 2001. View Article : Google Scholar : PubMed/NCBI
8	Zhou XZ, Kops O, Werner A, et al: Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell. 6:873–883. 2000. View Article : Google Scholar : PubMed/NCBI
9	Arnold HK, Zhang X, Daniel CJ, et al: The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J. 28:500–512. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ryo A, Nakamura M, Wulf G, Liou YC and Lu KP: Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol. 3:793–801. 2001. View Article : Google Scholar : PubMed/NCBI
11	Pathan N, Aime-Sempe C, Kitada S, Basu A, Haldar S and Reed JC: Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1. Neoplasia. 3:550–559. 2001. View Article : Google Scholar
12	Ryo A, Liou YC, Lu KP and Wulf G: Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. J Cell Sci. 116:773–783. 2003. View Article : Google Scholar : PubMed/NCBI
13	Ayala G, Wang D, Wulf G, et al: The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 63:6244–6251. 2003.PubMed/NCBI
14	Ryo A, Liou YC, Wulf G, Nakamura M, Lee SW and Lu KP: PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol. 22:5281–5295. 2002. View Article : Google Scholar : PubMed/NCBI
15	Ryo A, Uemura H, Ishiguro H, et al: Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer. Clin Cancer Res. 11:7523–7531. 2005. View Article : Google Scholar : PubMed/NCBI
16	Lu J, Yang L, Zhao H, et al: The polymorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in Southern and Eastern Chinese populations. Hum Mutat. 32:1299–1308. 2011. View Article : Google Scholar : PubMed/NCBI
17	Segat L, Milanese M and Crovella S: Pin1 promoter polymorphisms in hepatocellular carcinoma patients. Gastroenterology. 132:2618–2620. 2007. View Article : Google Scholar : PubMed/NCBI
18	Han CH, Lu J, Wei Q, et al: The functional promoter polymorphism (−842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat. 122:243–249. 2010.
19	Naidu R, Har YC and Taib NA: Analysis of peptidyl-propyl-cis/trans isomerase 1 (PIN1) gene −842(G > C) and −667(T > C) polymorphic variants in relation to breast cancer risk and clinico-pathological parameters. Scand J Clin Lab Invest. 71:500–506. 2011.
20	Lu J, Hu Z, Wei S, et al: A novel functional variant (−842G>C) in the PIN1 promoter contributes to decreased risk of squamous cell carcinoma of the head and neck by diminishing the promoter activity. Carcinogenesis. 30:1717–1721. 2009.
21	Lu Y, Huang GL, Pu XX, et al: Association between PIN1 promoter polymorphisms and risk of nasopharyngeal carcinoma. Mol Biol Rep. 40:3777–3782. 2013. View Article : Google Scholar : PubMed/NCBI
22	You Y, Deng J, Zheng J, et al: Functional polymorphisms in PIN1 promoter and esophageal carcinoma susceptibility in Chinese population. Mol Biol Rep. 40:829–838. 2013. View Article : Google Scholar : PubMed/NCBI
23	Handoll HH: Systematic reviews on rehabilitation interventions. Arch Phys Med Rehabil. 87:8752006. View Article : Google Scholar : PubMed/NCBI
24	Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
25	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
26	Whitehead A and Whitehead J: A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med. 10:1665–1677. 1991. View Article : Google Scholar : PubMed/NCBI
27	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
28	Bao L, Kimzey A, Sauter G, Sowadski JM, Lu KP and Wang DG: Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol. 164:1727–1737. 2004. View Article : Google Scholar : PubMed/NCBI
29	Arboleda MJ, Lyons JF, Kabbinavar FF, et al: Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 63:196–206. 2003.PubMed/NCBI
30	Fukuchi M, Fukai Y, Kimura H, et al: Prolyl isomerase Pin1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclinD1 expression. Int J Oncol. 29:329–334. 2006.PubMed/NCBI